beta-globin-transduced autologous hematopoietic stem cell therapy (Helix Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Namebeta-globin-transduced autologous hematopoietic stem cell therapy (Helix Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionHemoglobin beta chain stimulants
TargetsHemoglobin beta chain
Therapy Area/Indicationsbeta-ThalassemiaAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHelix Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHelix Therapeutics
Active IndicationsN/A
Inactive Indicationsbeta-ThalassemiaAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A